Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Total Current Liabilities (2016 - 2025)

Regenxbio (RGNX) has 12 years of Total Current Liabilities data on record, last reported at $118.1 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 14.44% year-over-year to $118.1 million; the TTM value through Dec 2025 reached $118.1 million, up 14.44%, while the annual FY2025 figure was $118.1 million, 14.44% up from the prior year.
  • Total Current Liabilities reached $118.1 million in Q4 2025 per RGNX's latest filing, down from $124.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $130.5 million in Q4 2021 and bottomed at $84.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $113.6 million, with a median of $116.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 164.12% in 2021, then decreased 20.79% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $130.5 million in 2021, then fell by 0.03% to $130.4 million in 2022, then decreased by 0.12% to $130.3 million in 2023, then dropped by 20.79% to $103.2 million in 2024, then increased by 14.44% to $118.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $118.1 million in Q4 2025, $124.6 million in Q3 2025, and $119.5 million in Q2 2025.